1. Introduction {#sec0001}
===============

Metabolic flexibility is defined as the capacity to switch from predominantly fat oxidation while fasting, to carbohydrate oxidation in the insulin-stimulated state as defined by Kelley and Mandarino [@bib0001]. Rates of fat- and carbohydrate oxidation can be measured by determining whole body oxygen consumption and carbon dioxide production by indirect calorimetry. Performing indirect calorimetry measurements in the fasted and insulin stimulated state thereby allows assessment of metabolic flexibility*.* Decreased metabolic flexibility is an early hallmark in the development of type 2 diabetes mellitus. Impairments in metabolic flexibility are not only present in patients with type 2 diabetes but also in a pre-diabetic state, in individuals with so-called impaired glucose tolerance (IGT) [@bib0002]. Decreased metabolic flexibility in these individuals results in delayed postprandial glucose clearance and thereby eventually leads to disturbances in glucose homeostasis. Therefore, improving metabolic flexibility in people with IGT may be a good strategy to delay, mitigate and/or prevent disturbed glucose homeostasis.

It has recently been suggested that the formation of acetylcarnitine is crucial in maintaining metabolic flexibility, resulting in improved glucose homeostasis [@bib0003], [@bib0004], [@bib0005], [@bib0006]. Acetylcarnitine is synthesized by the conjugation of acetyl-CoA and free carnitine, mediated via the enzyme carnitine acyltransferase (CrAT) [@bib0003], [@bib0004], [@bib0005], [@bib0006]. This enzyme acts as a buffering system to prevent extreme fluctuations in acetyl-CoA and free CoA availability. Buffering of the acetyl and free CoA pools is especially important during physiological conditions that cause substantial shifts in mitochondrial substrate supply and demand, such as (over)feeding and exercise. Acetyl-CoA is an allosteric regulator of mitochondrial enzymes and high levels of acetyl-CoA have been linked to states of metabolic inertia. This may be caused by nutrient overabundance which can lead to conflicting signals controlling mitochondrial substrate traffic and selection. Thus, the inflow of acetyl-CoA from fatty acid oxidation can override signaling from insulin to switch from lipid catabolism to glucose use, resulting in metabolic inflexibility and a muted response to a carbohydrate meal [@bib0006]. Conversely, sequestration of free CoA might limit maximal rates of β-oxidation during fasting. In accordance, knocking-out the CrAT enzyme in mice results in lower acetylcarnitine formation and blunted metabolic flexibility during feeding and exercise. Furthermore, CrAT gain-of function studies in human primary myotubes showed elevated mitochondrial acetylcarnitine efflux, indicating enhanced acetylcarnitine formation with higher CrAT enzyme activity [@bib0003], resulting in higher pyruvate dehydrogenase (PDH) activity and metabolic flexibility [@bib0003]. These results suggest an important role for acetylcarnitine formation in maintaining metabolic flexibility.

When lipid supply to the mitochondria exceeds demand and/or enzymatic capacity, a mismatch between β-oxidation and TCA cycle flux can result in accumulation of β-oxidation intermediates, such as long chain acyl-CoA and long chain acylcarnitine species [@bib0006], [@bib0007]. Indeed, elevated long-chain acylcarnitines were reported in insulin resistance and in conditions of blunted metabolic flexibility [@bib0008]. The 'trapping' of free carnitine and free CoA due to accumulation of long chain acyl groups may limit acetylcarnitine synthesis, as free carnitine availability is crucial for maintaining the buffering capacity of CrAT [@bib0003], [@bib0004], [@bib0009]. Therefore, next to low CrAT activity, decreased carnitine availability may also contribute to the development of metabolic inflexibility. For example, it was found that diabetic mice (beta actin promotor (BAP) agouti transgenic mice) were characterized by reduced acetylcarnitine concentrations in muscle, which could be restored to levels of non-diabetic mice by carnitine supplementation [@bib0009]. This was accompanied by improved metabolic flexibility, insulin sensitivity and restoration of blood glucose levels [@bib0009]. Furthermore, Noland et al. [@bib0004] found that feeding rats a chronic high-fat diet decreased the availability of free carnitine and hampered metabolic flexibility. Again, supplementation of carnitine in these rats restored metabolic flexibility and insulin sensitivity [@bib0004].

Whether carnitine supplementation can also improve metabolic flexibility in humans has so far not been studied. Moreover, it still remains elusive whether the beneficial effects of carnitine supplementation on metabolic flexibility and concomitantly improved glucose tolerance in humans relates to enhanced capacity to form acetylcarnitine. Intervention trials in humans have shown that oral carnitine supplementation can improve glucose tolerance in insulin resistant individuals with low carnitine status [@bib0010], [@bib0011], [@bib0012] and can have beneficial effects on glucose levels [@bib0013], [@bib0014], insulin levels [@bib0012] and markers of insulin resistance, such as the homeostatic model assessment of insulin resistance (HOMA-IR) index [@bib0012], [@bib0013] or glucose area under the curve after an oral glucose tolerance test [@bib0015]. These results seem to suggest that carnitine supplementation may enhance the capacity to form acetylcarnitine and improve metabolic flexibility in humans. To facilitate examination of this hypothesis, we recently set up a novel, proton magnetic resonance spectroscopy (^1^H-MRS) protocol, using long echo times, to repeatedly determine acetylcarnitine concentrations in skeletal muscle *in vivo* [@bib0016]. This technique provides the unique opportunity to non-invasively and dynamically investigate the role of acetylcarnitine formation in the development of metabolic inflexibility and type 2 diabetes. Using this non-invasive approach, we here aimed to investigate in humans if carnitine supplementation leads to increased intramuscular acetylcarnitine formation while also improving metabolic flexibility and insulin sensitivity in individuals with impaired glucose tolerance.

2. Methods {#sec0002}
==========

2.1. Ethical approval {#sec0003}
---------------------

The study protocol was approved by the institutional Medical Ethical Committee and conducted in accordance with the declaration of Helsinki. Monitoring was performed by the Clinical Trial Center of Maastricht. The study was registered at clinicaltrials.gov with identifier NCT02072759.

2.2. Participants {#sec0004}
-----------------

Twelve normal glucose tolerant (NGT) and eleven impaired glucose tolerant (IGT) individuals were included. IGT was defined as a plasma glucose level between 7.8--11.1 mmol/L 2-h after an oral glucose tolerance test (OGTT) and NGT as plasma glucose levels \<7.8 mmol/L two hours after OGTT [@bib0004], [@bib0017]. Exclusion criteria were unstable body weight (weight gain or loss \>3 kg in the previous 3 months), engagement in exercise \>3 h a week, impaired renal and/or kidney function, uncontrolled hypertension, history of cardiovascular disease, MRI contra-indications and being vegetarian. Impairments in renal and/or kidney function were assessed via determination of plasma ASAT, ALAT, GGT, creatine and bilirubin. An electrocardiogram (ECG) and blood pressure measurement were performed to assess cardiovascular diseases and uncontrolled hypertension respectively. All screening measurements were evaluated by a medical doctor. All individuals gave written informed consent.

2.3. Experimental design and treatment {#sec0005}
--------------------------------------

The study was set up in a double blind, randomised cross-over design in volunteers with IGT. NGT volunteers served as control group for baseline comparison ([Fig. 1](#fig0001){ref-type="fig"}A). The study was conducted at Maastricht University, The Netherlands, between April 2014 and June 2016. IGT participants were randomly assigned [@bib0018] to two intervention periods: 36 days oral intake of placebo and carnitine (2000 mg/day of [l]{.smallcaps}-Carnitine tartrate (NOW foods, Bloomingdale, IL, USA)). The carnitine dosage was based on previous studies in humans reporting improvements in metabolic parameters after 2000 mg of oral carnitine supplementation [@bib0010], [@bib0013], [@bib0015], [@bib0019], [@bib0020], [@bib0021]. Participants consumed one 500-mg capsule in the morning during breakfast, one 500-mg capsule at noon during lunch and two 500-mg capsules in the evening during diner. In the morning of test-day 30 and 33, subjects did not take any supplements. During participation in the study, both NGT- and IGT-subjects were instructed to maintain their habitual diet and physical activity pattern. Furthermore, intake of food supplements was not aLowed to prevent additional intake of oral carnitine. Three days before the test days, participants refrained from strenuous physical activity. Wash-out was at least 4 weeks. Compliance was checked counting unused supplements and by measuring plasma acylcarnitines levels using tandem mass spectroscopy on day 0 and 33 [@bib0022]. Participants were asked to maintain their normal diet and physical activity pattern during participation in the study. Participants reported to the laboratory on a weekly basis (day 0,7,14,21,28,33) for a fasting blood sample, to check compliance and supply supplements for the next week. On day 30, 33 and 36 various measurements were performed as described below. NGT participants were subjected to the same measurements but without any intervention trial (no placebo and carnitine). Primary outcome was the effect of L-carnitine supplementation on metabolic flexibility and insulin sensitivity. Secondary outcome measures were acetylcarnitine formation and plasma and skeletal muscle acylcarnitine profiles.Fig. 1**Study outline.** In 1A, the outline of the double blind, randomised cross-over design is presented. In 1B, a flowchart of the meal test (day 30) is presented. Participants were asked to consume a standardized evening meal on the evening before. Participants reported to the laboratory at 06.00AM in the fasted state. First, baseline indirect calorimetry and ^1^H-MRS measurements were conducted. Between 07.45AM and 08.15AM, subjects consumed a high-energy breakfast. Directly after breakfast (*t* = 30) as well as 2.5 (*t* = 150) and 5.5 (*t* = 330) hours after the meal, MRS measurements were repeated. Indirect calorimetry was measured three times using a ventilated hood system (*t*=−90, *t* = 90, *t* = 270). A blood samples was taken prior to each MRS measurement. IC, indirect calorimetry (ventilated hood), ^1^H-MRS, proton magnetic resonance spectroscopy.Fig. 1

2.4. VO~2max~ and body composition {#sec0006}
----------------------------------

Before the start of the trial, participants underwent an incremental cycling test to determine maximal oxygen uptake (VO~2max~) and maximal power output (W~max~) for characterization of the participants. On the same day, body composition was determined by DXA (DXA, discovery A; Hologic).

2.5. Meal test {#sec0007}
--------------

On day 30, participants reported to the laboratory at 6:00 AM after an overnight fast and *in vivo* skeletal muscle acetylcarnitine concentrations were determined by ^1^H-MRS (see below). Subsequently, a meal test was performed ([Fig. 1](#fig0001){ref-type="fig"}B). To this end, a high-energy breakfast was provided to the participants at 8:00 AM (*t* = 0), which consisted of sausage rolls (65.5% energy from fat, 31.6% energy of carbohydrates, and 6.9% energy form proteins, total energy content was equal to 50% of the participants required daily energy intake, according to the Cunningham equation [@bib0023] with a correction factor of 1.3 for physical activity). Blood plasma was sampled repeatedly to measure plasma glucose, insulin, free fatty acids and triglycerides (at *t*=−45, *t* = 15, *t* = 150, *t* = 330 min). Before the meal, and at *t* = 90 min, and *t* = 270 min, indirect calorimetry measurements (Ventilated hood, Omnical, Maastricht Instruments, Maastricht University) were performed. The respiratory exchange ratio (RER) was used to determine metabolic flexibility (ΔRER~t=90-fasted~ and ΔRER~t=270-~*~t~* ~=~ ~90~) and substrate oxidation 1.5 h (*t* = 90 min) and 4.5 h (*t* = 270 min) after consumption of the breakfast.

2.6. Hyperinsulinemic-euglycemic clamp {#sec0008}
--------------------------------------

On day 33, a one-step hyperinsulinemic-euglycemic clamp was performed to assess peripheral insulin sensitivity [@bib0024]. Subjects reported to the laboratory at 7:30 AM after an overnight fast. A fasted blood sample was taken and subsequently a primed-continuous infusion of [d]{.smallcaps}-\[6,6--^2^H~2~\]-glucose (16.8 mg/mL, 0.04 ml/kg/min) was started to determine rates of glucose appearance (R~a)~, glucose disappearance (R~d~) and endogenous glucose production (EGP) [@bib0025]. After 2 h (*t* = 120 min), infusion of insulin (40 mU/m^2^/min) was started for 2.5 h. During the basal period (*t* = 90--120 min) and the last 30 min of insulin infusion (*t* = 240--270 min) blood samples were collected and indirect calorimetry (ventilated hood) was performed to assess metabolic flexibility and substrate utilization according to Peronnet et al. [@bib0026]. Isotopic enrichment of plasma glucose was determined by electron ionization gas chromatography-mass spectrometry as described previously [@bib0027]. Steele\'s single pool non-steady state equations were used to calculate glucose R~a~ and R~d~ [@bib0025]. Volume of distribution was assumed to be 0.160 L/kg for glucose.

2.7. Muscle biopsy {#sec0009}
------------------

On the morning of the hyperinsulinemic euglycemic clamp, a muscle biopsy was taken from the vastus lateralis muscle according to the Bergström method [@bib0028]. Muscle tissue was frozen in melting isopentane and stored at --80 °C until further processing. Skeletal muscle acylcarnitines were analysed as previously described using electrospray tandem mass spectrometry [@bib0029]. Glycogen concentration was determined by using a commercial glycogen assay kit (ab65620, Abcam, Cambridge, United Kingdom) according to instructions of the manufacturer.

2.8. Cycling test {#sec0010}
-----------------

Finally, on a third test day (day 36), participants reported to the laboratory at 4:30 PM. After consumption of a light lunch at 12:00 AM, participants remained fasted for the following 5 h and refrained from physical activity. After arrival at the laboratory, subjects rested for 30 min. At 5:00 PM, baseline skeletal muscle acetylcarnitine concentrations were measured by ^1^H-MRS. Subsequently, a 30-min cycling exercise at 70% of the participants predetermined maximal power output (W~max~) was performed on an ergometer in a room next to the MR scanner. Directly after the exercise, quantification of acetylcarnitine was repeated.

2.9. ^1^H-MRS (acetylcarnitine) {#sec0011}
-------------------------------

Acetylcarnitine was quantified as reported earlier on a 3T clinical MR scanner (Achieva 3T-X, Philips Healthcare, Best, The Netherlands [@bib0016]. Spectra were acquired with the following acquisition parameters: TR=6000, spectral bandwidth 2 kHz and number of acquired data points 2048. A series of spectra were acquired with variable TE and NSA (300--12, 325--16, 350--20, 400--32, 450--52, 500--76 respectively). Due to considerable lipid contamination, acetylcarnitine concentration was analysed in spectra with TE=500 ms as the shorter echo times showed considerable lipid contamination in overweight participants. Using this method, the detection limit is approximately 0.15 mM.

Baseline correction was performed for all acquired spectra with a custom-made MATLAB script (The Mathworks Inc.). Spectra were analysed using the AMARES algorithm in jMRUI software [@bib0030]. The creatine resonance (t-Cr) was used as internal reference and acetylcarnitine concentration was calculated assuming a creatine concentration of 30 mmol/kg ww. T~2~ corrections were performed for creatine (T~2~=166 ms) and acetylcarnitine (T~2~=262 ms) and a correction for the dipolar coupling of creatine was applied and set at 30% of the signal as reported earlier [@bib0016].

2.10. Sample size and statistics {#sec0012}
--------------------------------

The effect of oral supplementation of carnitine on insulin sensitivity as determined by the clamp technique, has not been investigated yet. Therefore, the sample size was calculated based on the results from carnitine infusion studies which show clinically significant improvements of about 9.4% in parameters of insulin sensitivity during a hyperinsulinemic-euglycemic [@bib0031], [@bib0032]. The intraindividual variation (SD) of the difference in insulin sensitivity in repeated measurements is reported to be around 10% [@bib0024], [@bib0033], [@bib0034]. To reach 80% power and a significance level of 0.05 (two-sided) a minimal calculated sample size of *N* = 11 was needed. Data are presented as means ± SEM. Statistical analysis were performed using SPSS 24.0 software (SPSS, Chicago, IL.). Results were considered significantly different when *p*\<0.05 (two-sided testing). To evaluate if the data were normally distributed a Shapiro-Wilk normality test was performed. Student\'s paired *t*-test were performed to compare the intervention trials (carnitine and placebo). NGT and IGT participants were compared by Student\'s independent sample t-tests. Potential carry-over effect between treatment and period as well as period effect were examined by unpaired *t*-test analyses according to Pocock et al. [@bib0035]. No carry-over or period effects were found. Using individual data, Pearson correlation coefficients were calculated to test for associations between parameters. A mixed model repeated measures ANOVA was conducted to investigate changes in meal-induced metabolic flexibility, plasma metabolites (C0 and C2) and skeletal muscle acetylcarnitine concentrations assessed by ^1^H-MRS. Likewise, plasma metabolites before, during and after 30 days of carnitine and placebo treatment were assessed using a mixed model repeated measures ANOVA. Post-hoc analysis were performed and Bonferroni correction was applied to correct for multiple testing.

3. Results {#sec0013}
==========

3.1. Subject characteristics {#sec0014}
----------------------------

Body composition and maximal oxygen uptake (VO~2~max) were comparable between groups. Fasting glucose levels were slightly higher in IGT participants (*p* = 0.034) and, by design, glucose levels 120 min after an oral glucose tolerance test (OGTT~120~) were higher in IGT (*p*\<0.01). Also insulin levels at *t* = 120 min of the OGTT were significantly different between groups (*p* = 0.01). Fasting insulin, cholesterol and triglyceride levels were similar across groups at the onset of the study. Baseline characteristics are reported in [Table 1](#tbl0001){ref-type="table"}. Carnitine supplementation did not alter fasting plasma glucose, insulin, cholesterol, triglycerides and liver function ([Table 2](#tbl0002){ref-type="table"}).Table 1Baseline participant characteristics.Table 1NGT (*n* = 12)IGT (*n* = 11)Sex (m/f)10 / 210 / 1Age (y)61 ± 262 ± 2BMI (kg/m^2^)28.9 ± 0.729.7 ± 0.5**Body composition**Fat mass (kg)26.8 ± 1.827.0 ± 1.1Fat free mass (kg)64.0 ± 2.564.2 ± 2.9Fat percentage (%)29.6 ± 1.929.8 ± 1.0Visceral adipose tissue (kg)0.6 ± 0.10.8 ± 0.1**Physical fitness**VO~2~max (ml[\*](#tb1fn1){ref-type="table-fn"}min^−1^[\*](#tb1fn1){ref-type="table-fn"}kg^−1^)29.7 ± 1.528.3 ± 1.4Wmax (W[\*](#tb1fn1){ref-type="table-fn"}kg^−1^)2.2 ± 0.12.3 ± 0.1**Oral glucose tolerance test (OGTT)**Fasting glucose (mmol/L)5.3 ± 0.15.7 ± 0.1[\*](#tb1fn1){ref-type="table-fn"}Glucose OGTT~120~ (mmol/L)4.6 ± 0.38.2 ± 0.3[\*](#tb1fn1){ref-type="table-fn"}Fasting insulin (pmol/L)56.6 ± 9.180.1 ± 14.2Insulin OGTT~120~ (pmol/L)223.5 ± 36.1669.3 ± 149.3[\*](#tb1fn1){ref-type="table-fn"}**Blood lipid profile**Total cholesterol (mmol/L)5.6 ± 0.25.3 ± 0.1HDL cholesterol (mmol/L)1.5 ± 0.21.3 ± 0.1LDL cholesterol (mmol/L)3.4 ± 0.23.2 ± 0.2Triglycerides (mmol/L)1.64 ± 0.361.76 ± 0.28[^1]Table 2Plasma metabolites before and after 30 days of carnitine and placebo.Table 2IGT placeboIGT carnitineP-value**Glucose (mmol/L)**\
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3.2. Elevations in plasma free carnitine and acetylcarnitine levels {#sec0015}
-------------------------------------------------------------------

A time\*group interaction was found for plasma free carnitine (*p*\<0.001) and acetylcarnitine concentrations (*p* = 0.021). Plasma free carnitine (C0) and acetylcarnitine (C2) concentrations were similar at the beginning of placebo and carnitine treatment (*p*\>0.99 and *p* = 0.687 respectively). Upon carnitine supplementation, plasma free carnitine as well as acetylcarnitine concentrations increased in all individuals (C0 from 40.8 ± 1.6 to 50.5 ± 1.7 µmol/L, *p*\<0.001 and C2 from 6.6 ± 0.4 to 8.3 ± 0.6 µmol/L, *p* = 0.034, [Fig. 2](#fig0002){ref-type="fig"}A and B), indicating compliance to the study protocol. Carnitine levels did not change after placebo treatment (C0 from 39.4 ± 1.4 to 39.8 ± 1.3 µmol/L, *p* = 0.770 and C2 from 6.0 ± 0.4 to 6.2 ± 0.3 µmol/L, *p* = 0.538, [Fig. 2](#fig0002){ref-type="fig"}A and B). No major side effect of the oral carnitine supplementation were reported. Only one IGT-subject experienced a slightly fishy body odor.Table 3Plasma acylcarnitine before and after 30 days of carnitine and placebo.Table 3NGTIGT placeboIGT carnitineIGT placeboIGT carnitineDay 0Day 0Day 0Day 33Day 33C042.48±1.1939.43±1.4440.77±1.5739.75±1.3150.52±1.66[a](#tb3fn1){ref-type="table-fn"}^,^[b](#tb3fn2){ref-type="table-fn"}^,^[c](#tb3fn3){ref-type="table-fn"}C25.52±0.355.95±0.366.63±0.446.24±0.358.28±0.61[a](#tb3fn1){ref-type="table-fn"}^,^[b](#tb3fn2){ref-type="table-fn"}^,^[c](#tb3fn3){ref-type="table-fn"}C30.44±0.020.42±0.040.45±0.050.47±0.030.55±0.04C40.35±0.010.31±0.010.33±0.030.32±0.020.34±0.02C5:10.01±0.000.01±0.000.01±0.000.01±0.000.00±0.00C50.11±0.010.09±0.010.10±0.010.09±0.010.10±0.01C4-3OH0.04±0.010.04±0.010.06±0.010.04±0.010.04±0.01C60.08±0.010.08±0.010.08±0.010.07±0.010.08±0.01C5OH0.01±0.000.01±0.000.01±0.000.01±0.000.01±0.00C80.21±0.030.23±0.020.25±0.030.20±0.020.23±0.03C3 DC0.06±0.010.07±0.010.08±0.010.06±0.010.07±0.01C10:10.16±0.020.20±0.020.22±0.030.17±0.020.18±0.02C100.25±0.030.28±0.030.31±0.040.24±0.030.27±0.03C4 DC0.02±0.010.04±0.010.04±0.010.04±0.010.06±0.01C5 DC0.05±0.010.06±0.010.06±0.010.05±0.000.06±0.01C12:10.09±0.010.10±0.010.12±0.010.09±0.010.11±0.01C120.09±0.010.12±0.010.13±0.020.10±0.010.11±0.01C6 DC0.02±0.000.02±0.000.03±0.000.02±0.000.02±0.00C12:1OH0.03±0.010.07±0.040.04±0.010.03±0.010.03±0.01C12OH0.02±0.000.02±0.000.02±0.000.02±0.000.02±0.00C14:20.04±0.000.05±0.000.05±0.010.04±0.000.04±0.01C14:10.09±0.010.09±0.010.10±0.010.09±0.010.09±0.01C140.03±0.000.04±0.000.04±0.010.03±0.000.03±0.00C8 DC0.01±0.000.01±0.000.01±0.000.00±0.000.01±0.00C14:1OH0.02±0.000.02±0.000.02±0.000.01±0.000.02±0.00C14OH0.01±0.000.01±0.000.01±0.000.01±0.000.01±0.00C16:10.03±0.000.03±0.000.03±0.000.03±0.000.03±0.00C160.10±0.010.10±0.010.11±0.010.11±0.010.11±0.01C10 DC0.00±0.000.00±0.000.00±0.000.00±0.000.00±0.00C16:1OH0.01±0.000.01±0.000.01±0.000.01±0.000.01±0.00C16OH0.00±0.000.00±0.000.00±0.000.00±0.000.00±0.00C18:20.04±0.000.04±0.000.04±0.000.04±0.000.04±0.00C18:10.10±0.010.11±0.010.11±0.010.11±0.010.11±0.01C180.04±0.000.03±0.000.04±0.000.04±0.000.04±0.00C18:2OH0.00±0.000.00±0.000.00±0.000.00±0.000.00±0.00C18:1OH0.00±0.000.00±0.000.00±0.000.00±0.000.00±0.00C18OH0.00±0.000.00±0.000.00±0.000.00±0.000.00±0.00[^3][^4][^5]Fig. 2**Carnitine supplementation elevates plasma free carnitine and acetylcarnitine levels and rescues metabolic flexibility in IGT subjects during a hyperinsulinemic-euglycemic clamp as well as a high-energy meal test.** Plasma free carnitine concentrations (A) and plasma acetylcarnitine concentration (B). In A and B, black bars represent day 0 and white bars represent day 33 in NGT, IGT P (IGT placebo), and IGT C (IGT carnitine). Skeletal muscle glycogen concentrations (C). Metabolic flexibility during a hyperinsulinemic-euglycemic clamp was measured as the change from the fasted state to the insulin-stimulated state (ΔRER) (D), CHO oxidation (E), and lipid oxidation (F). In E and F, black bars represent the fasted state and white bars represent the insulin-stimulated state in NGT, IGT P (IGT placebo), and IGT C (IGT carnitine). \* insulin stimulated state significantly different from fasted state, \# different from insulin stimulated state NGT, \^ different from fasted state NGT and IGT on placebo (*p*\<0.05). Respiratory exchange ratio during a high-energy meal test (G), black bars represent ΔRER~t=90-basal~ and white bars represent ΔRER~t=270-~*~t~* ~=~ ~90~. \* significantly different from IGT on placebo, \# different from NGT. CHO oxidation (H), and lipid oxidation (I). In H and I, black bars represent the fasted state, white bars represent *t* = 90 min and grey bars represent *t* = 270 min after the meal in NGT, IGT P (IGT placebo), and IGT C (IGT carnitine). \* significantly different from fasted state, \^% different from *t* = 90 (*P*\<0.05). Values refer to twelve participants in the NGT group and nine participants in the IGT P and IGT C groups. Two IGT participants were not able to perform the meal test due to technical problems. All data are expressed as means ± SEM.Fig. 2

3.3. Carnitine supplementation restored metabolic flexibility but not insulin sensitivity during a hyperinsulinemic-euglycemic clamp {#sec0016}
------------------------------------------------------------------------------------------------------------------------------------

Metabolic flexibility, expressed as the change in respiratory exchange ratio upon insulin stimulation (ΔRER), was significantly lower in IGT compared to NGT participants ([Fig. 2](#fig0002){ref-type="fig"}D, *p* = 0.022). Interestingly, carnitine supplementation completely restored metabolic flexibility to NGT values in IGT-subjects ([Fig. 2](#fig0002){ref-type="fig"}D, *p*\<0.05). Overnight fasted lipid and carbohydrate oxidation rates were not different between NGT and IGT. However, carnitine supplementation increased overnight fasted basal lipid oxidation compared to placebo (*p* = 0.034), resulting in fat oxidation levels that were higher than in normal glucose tolerant participants ([Fig. 2](#fig0002){ref-type="fig"}F, *p* = 0.007). In line with the notion that fat- and carbohydrate oxidation rates generally exhibit reciprocal trends, basal carbohydrate oxidation was reduced on carnitine supplementation compared to the placebo group (*p* = 0.013) and tended to be lower in comparison with NGT participants ([Fig. 2](#fig0002){ref-type="fig"}E, *p* = 0.055). Substrate oxidation in the insulin-stimulated state was similar in the placebo and carnitine supplemented condition. Therefore, the change in metabolic flexibility (ΔRER) is driven by a change in basal substrate oxidation. Together with the reduction in carbohydrate oxidation in the fasted state in IGT participants upon carnitine supplementation, non-oxidative glucose disposal in the fasted state was increased (*p*\<0.05) in these volunteers, indicating that a larger fraction of the glucose taken up was incorporated into glycogen(27).

We also examined if carnitine supplementation had beneficial effects on peripheral insulin sensitivity and performed a hyperinsulinemic euglycemic clamp combined with deuterated glucose tracers. Basal EGP was lower in IGT participants compared to NGT (*p*\<0.01) but was not affected by carnitine supplementation (*p* = 0.962). Insulin-stimulated suppression of EGP was not significantly different between groups (*p*\>0.05).

As expected, the insulin-stimulated rate of disappearance of glucose (ΔR~d~) was significantly higher in NGT compared to IGT participants (*p*\<0.01, [Table 4](#tbl0004){ref-type="table"}). Carnitine supplementation did not significantly affect insulin stimulated glucose disposal (ΔR~d~: 11.74 ± 1.99 vs 13.32 ± 3.08 after placebo and carnitine respectively, *p* = 0.512). Interestingly, however, upon carnitine supplementation, a larger fraction of this insulin stimulated glucose disposal was directed towards glucose oxidation, thereby completely restoring the insulin-stimulated glucose oxidation in IGT towards levels observed in NGT ([Table 4](#tbl0004){ref-type="table"}). Conversely, carnitine supplementation reduced insulin-stimulated non-oxidative glucose disposal. These data suggest that, although carnitine supplementation did not affect peripheral insulin sensitivity, it did result in a redistribution of the glucose taken up after insulin stimulation towards oxidative disposal and less to glycogen storage.Table 4Substrate kinetics and insulin sensitivity.Table 4NGT (*n* = 12)IGT Placebo (*n* = 11)IGT Carnitine (*n* = 11)RER (arbitrary units AU) Basal0.798 ± 0.0080.791 ± 0.0120.762 ± 0.010[a](#tb4fn1){ref-type="table-fn"}^,^[b](#tb4fn2){ref-type="table-fn"} Insulin-stimulated0.899 ± 0.0090.857 ± 0.011[a](#tb4fn1){ref-type="table-fn"}0.863 ± 0.010[a](#tb4fn1){ref-type="table-fn"} Δ0.101 ± 0.0120.066 ± 0.007[a](#tb4fn1){ref-type="table-fn"}0.100 ± 0.010[b](#tb4fn2){ref-type="table-fn"}CHO oxidation (µmol\*kg^−1^\*min^−1^) Basal6.71 ± 0.615.93 ± 0.714,01 ± 0.66[a](#tb4fn1){ref-type="table-fn"}^,^[b](#tb4fn2){ref-type="table-fn"} Insulin-stimulated14.22 ± 0.7810.77 ± 0.7511.09 ± 0.79[a](#tb4fn1){ref-type="table-fn"} Δ7.51 ± 1.014.84 ± 0.487,08 ± 0.74[b](#tb4fn2){ref-type="table-fn"}Lipid oxidation (µmol\*kg^−1^\*min^−1^) Basal1.10 ± 0.051.12 ± 0.081.27 ± 0.07[a](#tb4fn1){ref-type="table-fn"}^,^[b](#tb4fn2){ref-type="table-fn"} Insulin-stimulated0.55 ± 0.050.77 ± 0.070.73 ± 0.06[a](#tb4fn1){ref-type="table-fn"} Δ−0.54 ± 0.07−0.35 ± 0.04−0.54 ± 0.05[b](#tb4fn2){ref-type="table-fn"}Rd glucose (µmol\*kg^−1^\*min^−1^) Basal10.80 ± 0.707.64 ± 0.49[a](#tb4fn1){ref-type="table-fn"}7.97 ± 0.80[a](#tb4fn1){ref-type="table-fn"} Insulin-stimulated36.51 ± 3.4819.38 ± 2.02[a](#tb4fn1){ref-type="table-fn"}21.29 ± 2.98[a](#tb4fn1){ref-type="table-fn"} Δ25.71 ± 3.3911.74 ± 1.99[a](#tb4fn1){ref-type="table-fn"}13.32 ± 3.08[a](#tb4fn1){ref-type="table-fn"}NOGD (µmol\*kg^−1^\*min^−1^) Basal5.41 ± 0.703.09 ± 0.49[a](#tb4fn1){ref-type="table-fn"}5.94 ± 0.80[b](#tb4fn2){ref-type="table-fn"} Insulin-stimulated23.16 ± 3.4810.98 ± 2.02[a](#tb4fn1){ref-type="table-fn"}9.08 ± 2.98[a](#tb4fn1){ref-type="table-fn"} Δ17.76 ± 3.397.89 ± 1.99[a](#tb4fn1){ref-type="table-fn"}3.15 ± 3.08[a](#tb4fn1){ref-type="table-fn"}Glucose (mmol/L) Basal5.5 ± 0.15.8 ± 0.1[a](#tb4fn1){ref-type="table-fn"}5.9 ± 0.1[a](#tb4fn1){ref-type="table-fn"} Insulin-stimulated5.5 ± 0.25.3 ± 0.15.2 ± 0.1Plasma insulin (pmol/L) Basal63.85 ± 11.4884.31 ± 9.1684.24 ± 11.48 Insulin-stimulated945.07 ± 52.391022.01 ± 43.04981.08 ± 5.56Plasma FFA (µmol/L) Basal522.86 ± 30.96612.00 ± 56.68597.4 ± 34.75 Insulin-stimulated72.31 ± 6.61119.90 ± 14.02[a](#tb4fn1){ref-type="table-fn"}110.30 ± 11.28[a](#tb4fn1){ref-type="table-fn"}[^6][^7]

3.4. Skeletal muscle glycogen concentrations {#sec0017}
--------------------------------------------

To directly test if carnitine supplementation affected baseline muscle glycogen concentrations, we measured glycogen concentration in the muscle biopsies. Muscle glycogen was not different between NGT and IGT participants (*p*\>0.05) in the fasted state. Although not significant, skeletal muscle glycogen concentrations tended to increase upon carnitine supplementation (*p* = 0.140, [Fig. 2](#fig0002){ref-type="fig"}C). These data are in line with a higher non-oxidative glucose disposal (NOGD) in the overnight fasted state upon carnitine supplementation (*p* = 0.006), suggesting that under basal conditions more glucose is shuttled towards glycogen storage. It also may explain the reduction in insulin-stimulated non-oxidative glucose disposal as basal glycogen levels are known to determine further rates of glycogen storage.

3.5. Metabolic flexibility is rescued in IGT-subjects during a high-energy meal test upon carnitine {#sec0018}
---------------------------------------------------------------------------------------------------

Next to the assessment of metabolic flexibility during a clamp, metabolic flexibility was also determined in a more physiological setting, upon a meal. In line with the results from the clamps, metabolic flexibility in response to a high-energy meal was also decreased in IGT and could be completely restored with carnitine supplementation (time\*group interaction *p*\<0.05, [Fig. 2](#fig0002){ref-type="fig"}G-I*)*. IGT participants on carnitine supplementation had a lower RER in the fasted state compared to placebo (*p* = 0.024) as well as when compared to NGT controls (*p* = 0.027). Although metabolic flexibility improved, meal-induced levels of plasma glucose, insulin, triacylglycerides and free fatty acids were unaffected by carnitine supplementation (time\*group interaction *p*\>0.05, [Fig. 3](#fig0003){ref-type="fig"}).Fig. 3**Plasma metabolites during the meal test**, glucose (A), free fatty acids FFA (B), triglycerides (C), insulin (D) analysed via a mixed model repeated measures ANOVA. No interaction effects (time\*group) were present for any of the plasma metabolites. The black line represents the NGT group, the striped line the IGT on placebo and the dotted line IGT on carnitine. Data are expressed as means ± SEM. \* significantly different (*p*\<0.05). Values refer to twelve participants in the NGT group and nine participants in the IGT P and IGT C groups. In two IGT participants, the meal test could not be performed due to technical problems.Fig. 3

3.6. Carnitine supplementation improves capacity to form acetylcarnitine in muscle {#sec0019}
----------------------------------------------------------------------------------

To investigate if the improved metabolic flexibility upon carnitine supplementation resulted in improved acetylcarnitine metabolism, we used ^1^H-MRS to determine acetylcarnitine levels in the vastus lateralis muscle. We first determined if carnitine supplementation would elevate overnight fasted acetyl-carnitine levels. Contrary to our expectations, skeletal muscle acetylcarnitine concentrations in the morning at 7:00 AM were not significantly different between NGT and IGT (0.37±0.09 vs 0.65±0.15 µmol/kgww respectively, *p* = 0.111), and if anything tended to be elevated in IGT. Also, carnitine supplementation did not alter muscle acetylcarnitine concentrations (0.44±0.12 mmol/kgww for carnitine, *p* = 0.674) as measured by ^1^H-MRS. These data match with the acetylcarnitine concentrations measured in biopsies where likewise, no difference between the groups or between the placebo and carnitine treatment were detected (see data below). Given the hypothesized role of acetyl-carnitine in metabolic flexibility, it can be expected that these levels are low in the overnight fasted state when the body mainly relies on fat as a substrate source. We therefore also measured acetylcarnitine levels later during the day. Interestingly, skeletal muscle acetylcarnitine levels were higher when measured at 5:00 PM as compared to 7:00 AM in NGT ([Fig. 4](#fig0004){ref-type="fig"}A and B), suggesting that acetylcarnitine levels in skeletal muscle rise during the day. Furthermore, a time\*group interaction was found (*p* = 0.028). Intriguingly, this increase in skeletal muscle acetylcarnitine levels during the day (assessed in a subset of 8 participants) was markedly blunted in the IGT group (delta acetylcarnitine concentration: 0.67± 0.18 vs 1.41 ± 0.33 µmol/kgww in IGT compared to NGT, *p* = 0.048, [Fig. 4](#fig0004){ref-type="fig"}A and B), but was completely restored upon carnitine supplementation (1.51 ± 0.33 mmol/kgww, *p* = 0.037). As a result, acetylcarnitine levels measured at 5:00 PM tended to be lower in IGT participants on placebo compared to NGT controls (1.08±0.20, 1.64±0.28 mmol/kgww for IGT and NGT respectively, *p* = 0.064) and in fact, carnitine supplementation restored acetylcarnitine levels towards values observed in NGT (1.62±0.27 mmol/kgww).Fig. 4**Carnitine supplementation improves capacity to form acetylcarnitine in muscle.** Skeletal muscle acetylcarnitine concentrations over the day (A) and delta acetylcarnitine concentrations (B). In A, a time\*group effect was reported (*p* = 0.028). The black line represents the NGT group, the striped line the IGT on placebo and the dotted line IGT on carnitine. \* IGT placebo significantly different from IGT placebo and NGT, \# IGT placebo significantly different from IGT on carnitine (*p*\<0.05). Values refer to twelve participants in the NGT group and eight participants in the IGT P and IGT C groups. Two IGT participants were not able to perform the 07:00AM measurement due to technical problems and one subject was excluded due to protocol violations. Therefore, these subjects were excluded from panel A. In C, skeletal muscle acetylcarnitine concentrations in the resting state and the capacity to form acetylcarnitine with exercise in NGT, IGT P (IGT placebo), and IGT C (IGT carnitine) are represented. \* significantly different from IGT on carnitine, \# tending to be different from NGT (*p* = 0.064). Values refer to twelve participants in the NGT group and eleven participants in the IGT P and IGT C groups. All data are expressed as means ± SEM.Fig. 4

Finally, we also determined the maximal capacity to form acetylcarnitine. Exercise is known to lead to an increase in skeletal muscle acetylcarnitine, possibly because substrate load into the mitochondria is rapidly increased upon exercise thereby elevating acetyl-CoA levels. At high exercise intensity, this increase in acetylcarnitine reflects the capacity individuals have to produce acetylcarnitine and can be seen as a parameter for free carnitine availability. Therefore, acetylcarnitine was measured in skeletal muscle before exercise (5:00 PM measurement) and after 30 min of exercise at 70% W~max.~ Acetylcarnitine levels in skeletal muscle increased in all three groups (*p*\<0.05), but post-exercise acetylcarnitine concentrations were markedly higher after carnitine supplementation compared to placebo (4.23±0.53 vs 3.60±0.49 mmol/kgww for carnitine and placebo respectively, *p* = 0.017) and reached NGT-levels (4.15±0.28 mmol/kgww, [Fig. 4](#fig0004){ref-type="fig"}C), suggesting that carnitine supplementation boosted the maximal capacity to form acetylcarnitine.

3.7. Lower whole body RER upon carnitine supplementation is related to more complete degradation of fat substrates {#sec0020}
------------------------------------------------------------------------------------------------------------------

A limitation of MRS is that only acetylcarnitine levels can be measured and no information is provided about other acylcarnitine species. Therefore, we examined the complete acylcarnitine profile in the muscle biopsies taken after an overnight fast after placebo or carnitine supplementation. As described above, over the whole group, concentrations of free carnitine (C0), acetylcarnitine (C2) and other short-chain acylcarnitine species were similar in muscle biopsies from NGT and IGT subjects (for C0: *p* = 0.416 and for C2: *p* = 0535), and unaffected by carnitine supplementation (for C0: *p* = 0.356 and for C2: *p* = 0.371). However, there were some interindividual differences and the subjects who showed the greatest change in carnitine availability upon supplementation also showed the greatest response in fat oxidation. Thus, the change in skeletal muscle free carnitine availability from placebo to carnitine treatment period correlated positively with the change in lipid oxidation in the fasted state (*r* = 0.66, *p* = 0.03, [Fig. 5](#fig0005){ref-type="fig"}A). Furthermore, the change in skeletal muscle acetylcarnitine concentrations also correlated positively with the change in lipid oxidation in the fasted state (*r* = 0.63, *p* = 0.04, [Fig. 5](#fig0005){ref-type="fig"}B).Fig. 5**Lower whole body RER upon carnitine supplementation is related to more complete degradation of fat substrates**. Difference in skeletal muscle free carnitine availability (C0 in mmol/kgww) and acetylcarnitine (C2 in mmol/kgww) between placebo and carnitine treatment, measured in biopsies. In A, basal free carnitine availability is related to the lipid oxidation in the fasted state (*r* = 0.66, *p* = 0.03), figure 8). In B, the basal acetylcarnitine concentration is related to the lipid oxidation (F0) in the fasted state (*r* = 0.63, *p* = 0.04). In C, C2 acetylcarnitine/Long-chain acyl carnitine ratio is related to the lipid oxidation in the fasted state (*r* = 068, *p* = 0.02). In D, skeletal muscle long-chain acylcarnitine concentrations measured in biopsies are represented. Black bars represent the NGT group, white bars the IGT on placebo and grey bars IGT on carnitine. Data are expressed as means ± SEM. \* IGT on carnitine significantly from IGT placebo (*p*\<0.05), \# IGT on carnitine tending to be different from IGT on placebo (*p*\<0.10), \^ IGT placebo tending to be different from NGT (*p*\<0.10).Fig. 5

Long-chain acylcarnitines were elevated in IGT on placebo compared to NGT (*p* = 0.047), suggesting less complete β-oxidation in IGT volunteers. Interestingly, carnitine supplementation actually lowered long-chain acylcarnitine species compared to placebo, (*p* = 0.027, [Fig. 5](#fig0005){ref-type="fig"}D, [Table 5](#tbl0005){ref-type="table"}). This observation suggests carnitine supplementation contributed to more complete β-oxidation. To gain further insight into changes in complete fat oxidation, we calculated the acetylcarnitine (C2)/Long-chain acyl carnitine ratio. Interestingly, the individuals that increased their fat oxidation the most also showed the greatest changes in the C2 acetylcarnitine/Long-chain acyl carnitine ratio, suggesting that the lower whole body RER upon carnitine supplementation is due to more complete degradation of fat substrates ([Fig. 5](#fig0005){ref-type="fig"}C)Table 5Skeletal muscle acylcarnitine concentration (in biopsies) before and after 30 days of carnitine and placebo.Table 5NGTIGT placeboIGT carnitineDay 33Day 33Day 33C06820.44±838.287647.93±495.588490.26±933.94C2644.88±80.30731.41±113.50885.53±175.97C310.96±1.3912.73±1.1812.91±1.34C49.41±1.3710.59±2.657.46±1.31C5:10.41±0.090.73±0.130.80±0.22C53.22±0.624.95±1.354.94±1.15C4-3OH2.59±0.414.55±1.354.62±1.25C65.75±1.557.54±2.543.79±1.36C5-OH1.03±0.241.51±0.291.48±0.32C8:11.03±0.171.26±0.190.78±0.10C83.24±1.083.59±1.221.82±0.51C3DC0.71±0.450.42±0.150.72±0.18C4DC1.77±0.601.42±0.201.48±0.20C101.78±0.652.18±0.741.30±0.49C5DC1.18±0.780.43±0.120.52±0.15C12:10.42±0.110.78±0.270.50±0.21C121.62±0.463.38±1.222.22±1.11C8:1DC or C12:1-OH0.12±0.020.19±0.050.21±0.05C8DC or C12-OH0.13±0.020.17±0.040.17±0.03C14:20.88±0.211.90±0.661.33±0.77C14:13.17±0.888.62±3.655.73±3.93C143.20±0.918.87±3.405.38±3.03C10:1DC or C14:1-OH0.32±0.050.62±0.140.48±0.13C16:20.61±0.172.55±0.93^d^0.98±0.62C16:13.21±0.9013.03±4.592.56±0.67C169.15±2.2418.58±5.3612.84±3.63[b](#tb5fn2){ref-type="table-fn"}C12:1DC or C16:1-OH0.31±0.040.59±0.160.43±0.11C18:23.22±0.855.29±1.353.50±0.84[a](#tb5fn1){ref-type="table-fn"}C18:110.72±2.6624.25±6.379.96±2.18[a](#tb5fn1){ref-type="table-fn"}C184.02±0.887.86±1.895.31±1.49[a](#tb5fn1){ref-type="table-fn"}C20:20.06±0.010.11±0.020.08±0.02C20:10.19±0.040.34±0.100.22±0.06[a](#tb5fn1){ref-type="table-fn"}C200.07±0.020.12±0.040.11±0.03[b](#tb5fn2){ref-type="table-fn"}Sum long-chain acylcarnitines39.12±9.6292.54±24.3348.92±16.01[a](#tb5fn1){ref-type="table-fn"}[^8][^9]

4. Discussion {#sec0021}
=============

Animal studies have indicated that free carnitine availability in skeletal muscle may be crucial in permitting the formation of acetylcarnitine and coincident maintenance of metabolic flexibility, as indicated by Noland et al. [@bib0004]. We here aimed to investigate in humans if carnitine supplementation augments acetylcarnitine formation and improves metabolic flexibility and insulin sensitivity in individuals with impaired glucose tolerance. In the current study we show that metabolic flexibility was lower in IGT compared to NGT participants and completely restored upon carnitine supplementation. Concomitantly, free carnitine availability in plasma increased. Likewise, in IGT volunteers, both the afternoon rise *in vivo* resting skeletal muscle acetylcarnitine concentrations and the maximal capacity to form acetylcarnitine during exercise were enhanced upon carnitine supplementation compared to placebo. These findings are in line with the notion that the capacity to form acetylcarnitine is important in mitochondrial substrate switching and may be limited by availability of free carnitine \[[@bib0003],[@bib0004]\]. Interestingly, improved metabolic flexibility was not only measured during the hyperinsulinemic euglycemic clamp, but also in a more physiological setting upon consumption of an energy-rich meal. Together, these data suggest that, similar to the preclinical studies, carnitine supplementation in humans may help to improve metabolic flexibility via increasing skeletal muscle acetylcarnitine levels.

In the current study, we determined acetylcarnitine concentrations *in vivo* using ^1^H-MRS both in the morning after an overnight fast as well as in the afternoon. Interestingly, acetylcarnitine concentrations were consistently higher in the afternoon compared to the morning, suggesting that acetylcarnitine levels rise during the day. This increase in acetylcarnitine levels during the day fits with a role of muscle acetylcarnitine in facilitating metabolic flexibility, as it is known that after an overnight fast the body mainly relies on fatty acid oxidation, whereas daytime feeding provides mitochondria with a mixture of fuels [@bib0001]. Strikingly, this increase in acetylcarnitine over the day was substantially blunted in IGT, leading to significant differences in acetylcarnitine concentrations between the groups in the afternoon, which were not detectable in the morning. Interestingly, upon carnitine supplementation the increase of acetylcarnitine levels during the day was completely restored to NGT levels, which makes it tempting to speculate that the variation in acetylcarnitine levels over the day may be related to flexibility in substrate use.

Underlying mechanisms of improved metabolic flexibility upon carnitine supplementation are yet unknown, but indirect calorimetry showed that lipid oxidation in the fasting state was increased, presumably sparing glycogen stores. In line with the latter, muscle glycogen concentrations and non-oxidative glucose disposal rate in the basal, fasted state were enhanced upon carnitine supplementation. [L]{.smallcaps}-carnitine is best recognized for its role as an obligate substrate for carnitine palmitoyl transferase 1 (CPT1), which synthesizes long chain acylcarnitines at the outer mitochondrial membrane and thereby permits transfer of long chain acyl groups into the matrix. Thus, diminished CPT1 activity due enzyme inhibition and/or carnitine insufficiency could limit rates of fat oxidation. However, as muscle carnitine concentrations are in far excess of the *in vitro* Michaelis Menten constant of CPTI in human muscle, carnitine is generally not assumed to be limiting to CPTI flux [@bib0036]. Nevertheless, some studies investigated the impact of carnitine on substrate oxidation and maximal performance in trained athletes and found that fat oxidation during exercise was increased and maximal performance improved. However, this was found indeed without affecting CPTI activity [@bib0037], [@bib0038], arguing against increased CPTI flux underlying the changes found after carnitine supplementation. Nevertheless discussion remains on whether compartmentalization may play a role and that specifically mitochondrial carnitine concentration may be of relevance [@bib0039]. In the current study, we find improvements of whole body fat oxidation in the resting state, and also here it is unlikely that an increased CPTI flux is underlying our findings, as the elevated fat oxidation in the current study is not linked to accumulation of long chain acyl-carnitines. The accumulation of long-chain acylcarnitines in skeletal muscle has previously been reported in situations when high lipid availability drives fat oxidation. Under such circumstances, long chain acylcarnitine production by CPT1 surpasses downstream capacity of the beta-oxidation enzymes, resulting in incomplete fat oxidation and potential trapping of both carnitine and CoA moieties [@bib0004], [@bib0006], [@bib0007]. In the current study, the rise in whole-body fat oxidation that occurred in response to carnitine supplementation was accompanied by decreased levels of skeletal muscle long-chain acylcarnitines, strongly suggesting that CPT1 flux was not the limiting factor during the placebo arm of the trial. Instead, the findings imply that carnitine supplementation improved fat oxidative capacity by promoting acyl-CoA flux through the entire beta-oxidation spiral, resulting in more complete degradation of long chain fatty acids to acetyl-CoA and CO~2~.

Although some studies were performed on the effect of carnitine on substrate metabolism during exercise and maximal performance, to our knowledge, it has not been investigated whether carnitine can beneficially influence substrate oxidation in the resting state in humans and whether it can thereby affect the meal-induced increment of carbohydrate oxidation. Here, we investigated this in a highly relevant population of volunteers with impaired glucose tolerance and therefore at increased risk of developing type 2 diabetes and found that indeed, carnitine supplementation resulted in a more pronounced switch between fat oxidation in the fasted state and carbohydrate oxidation in the insulin-stimulated state based on the RQ data measured with indirect calorimetry. The importance of diurnal changes in substrate oxidation and the beneficial metabolic effects of reaching a truly fasted state with strong reliance on fat oxidation is becoming increasingly recognized [@bib0040].

Despite the effects of carnitine supplementation on skeletal muscle acetylcarnitine concentration and metabolic flexibility, no changes in insulin sensitivity were observed in the current study. Although the current study cannot reveal the reason for this lack of effect on insulin sensitivity, previous results suggest that the duration of the carnitine supplementation may have been too short to improve insulin sensitivity. Thus, Gonzalez-Ortiz et al. [@bib0041] and Galloway et al. [@bib0042] did not report changes in glucose homeostasis after four and two weeks of 3 g [L]{.smallcaps}-Carnitine supplementation respectively. Indeed, changes in fasting plasma glucose and insulin, as well as improved HOMA-IR indices were observed upon 12, 24 and 48 weeks of oral [L]{.smallcaps}-carnitine supplementation suggesting that the duration of 36 days as in our study might be too short to improve insulin sensitivity. Future studies are therefore needed to reveal if longer duration of carnitine supplementation would result in improved insulin sensitivity.

A limitation of the current study is the small number of female subjects included (*n* = 3). Although no restrictions were applied for females participating in the study, recruitment of females was very difficult, resulting in a majority of male subjects. Even though the response to carnitine in females did not appear different than in male participants in the current study, the number of subjects is too low to draw definitive conclusions and future research will have to investigate in more detail whether the results can be translated to a female population.

In conclusion, we here show that carnitine supplementation has very pronounced effects on metabolic flexibility in impaired glucose tolerant volunteers, and in fact can completely restore metabolic flexibility. Carnitine supplementation enhanced the increase in acetylcarnitine concentration in resting muscle throughout the day, as well as the capacity to form acetylcarnitine in response to exercise. These changes in acetylcarnitine formation may be underlying the beneficial effects on metabolic flexibility. Longer studies are needed to investigate if carnitine supplementation can also improve insulin sensitivity. Taken together, carnitine supplementation may be an interesting aid in improving disturbed metabolism in subjects prone to develop type 2 diabetes mellitus.

Declaration of Competing Interest {#sec0024}
=================================

The authors declare no competing interest.

CRediT authorship contribution statement {#sec0024a}
========================================

**Yvonne MH Bruls:** Methodology, Formal analysis, Investigation, Writing - original draft, Project administration. **Marlies de Ligt:** Investigation, Writing - review & editing. **Lucas Lindeboom:** Methodology, Writing - review & editing. **Esther Phielix:** Methodology, Writing - review & editing. **Bas Havekes:** Investigation, Writing - review & editing. **Gert Schaart:** Formal analysis. **Esther Kornips:** Formal analysis. **Joachim E Wildberger:** Writing - review & editing, Supervision. **Matthijs KC Hesselink:** Conceptualization, Methodology, Writing - review & editing, Supervision. **Deborah Muoio:** Conceptualization, Writing - review & editing. **Patrick Schrauwen:** Conceptualization, Methodology, Writing - review & editing, Supervision, Project administration. **Vera B Schrauwen-Hinderling:** Conceptualization, Methodology, Writing - review & editing, Supervision, Project administration, Funding acquisition.

Appendix. Supplementary materials {#sec0030}
=================================

Image, application 1

Acknowledgments {#sec0022}
===============

This study was funded by a European Foundation for the Study of Diabetes Clinical Research Grant. Vera Schrauwen-Hinderling was supported by a grant from the European Research Council (ERC-2017-StG-75961 MRS in diabetes. The authors greatly thank all research volunteers for participating in the study.The authors would like to thank Fred Vaz from the Core Facility Metabolomics of the Amsterdam University Medical Center for his help with analyzing the acetylcarnitine species.

Funding {#sec0023}
=======

The funding source did not play a role other than financial support.

Research in context {#sec0025}
===================

Type 2 diabetes patients and individuals at risk of developing diabetes are characterized by metabolic inflexibility and disturbed glucose homeostasis. Low carnitine availability may contribute to metabolic inflexibility and impaired glucose tolerance as suggested based on animal studies. Whether carnitine supplementation can also improve metabolic flexibility in humans has so far not been studied. Therefore, we investigated whether carnitine supplementation improves metabolic flexibility and insulin sensitivity in impaired glucose tolerant (IGT) volunteers.
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Metabolic flexibility was completely restored upon carnitine supplementation in IGT volunteers. Furthermore, carnitine enhanced the increase in resting skeletal muscle acetylcarnitine concentrations over the day (delta 7:00 AM-5:00 PM). Long-chain acylcarnitine species were reduced after carnitine supplementation, suggesting the stimulation of a more complete fat oxidation in muscle.
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Carnitine supplementation may provide new opportunities in the prevention and/or treatment of type 2 diabetes which require further investigation.
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[^1]: *p*\<0.05, IGT significantly different from NGT. Wmax, maximal workload.

    Data are represented as mean ± SEM.

[^2]: Data are expressed as mean ± SEM. P-value reflect time\*treatment effect by mixed model repeated measures ANOVA. Bonferroni correction was performed to correct of multiple testing Plasma values are obtained after an overnight fast. There were no missing data in these parameters.

[^3]: significantly different from day 0.

[^4]: different from IGT on placebo at day 33,.

[^5]: significantly different from NGT day 33. Post-hoc analysis were performed and Bonferroni correction was applied to correct of multiple testing after a significant time\*treatment effect by mixed model repeated measures ANOVA. To prevent multiple testing, the other single acylcarnitine species are displayed but not tested for statistical significance.

    Data are expressed as mean ± SEM. Statistical significance of the differences in C0 and C2 were tested as described.

[^6]: IGT placebo or IGT carnitine significantly different from NGT.

[^7]: IGT carnitine significantly different from IGT placebo.

    Data are expressed as mean ± SEM.

[^8]: significantly different from IGT placebo,.

[^9]: tending towards a difference from IGT on placebo

    Data are expressed as mean ± SEM.
